France· FR:66367812
OPDIVO 10 mg/ml, solution a diluer pour perfusion
A medicinal product containing nivolumab, registered in France by BRISTOL-MYERS SQUIBB PHARMA (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- NIVOLUMAB
- Manufacturer
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 4
- cip1334009550057971 flacon(s) en verre de 4 ml
- cip1334009550058031 flacon(s) en verre de 10 ml
- cip1334009550555701 flacon(s) en verre de 24 ml
- cip1334009550855221 flacon(s) en verre de 12 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nivolumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsOpdivo 10 mg/ml, concentraat voor oplossing voor infusieBristol-Myers Squibb Pharma EEIG
- SpainOPDIVO 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- United KingdomNivolumab BMS 100mg/10ml concentrate for solution for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- United StatesOPDIVOE.R. Squibb & Sons, L.L.C.
- FinlandNivolumab BmsBristol-Myers Squibb Pharma EEIG
- BelgiumOpdivo 10 mg/mlBristol-Myers Squibb Pharma
- CzechiaOPDIVOBristol-Myers Squibb Pharma EEIG, Dublin
- SwitzerlandOpdivo 100 mg/10 ml, Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Opdivo
- Liechtenstein · Opdivo
- Norway · Opdivo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da6f3332-9b34-48e7-9fc3-0c75fa1298ed GET /v1/drugs/da6f3332-9b34-48e7-9fc3-0c75fa1298ed?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66367812",
"date_amm": "2015-06-19",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/15/1014",
"substance": "NIVOLUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about nivolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.